Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Plx-9486
2. 2roq545lag
3. Cgt9486
4. Plx 9486 [who-dd]
5. 4,5-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-3-carboxamide
6. 1616385-51-3
7. 3,4-dimethyl-n-(2-phenyl-1h-pyrrolo(2,3-b)pyridin-5-yl)-1h-pyrazole-5-carboxamide
8. 3,4-dimethyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-pyrazole-5-carboxamide
9. Unii-2roq545lag
10. Bezuclastinib [inn]
11. Schembl15824576
12. Gtpl11868
13. Plx9486
14. Bdbm392363
15. Cgt-9486
16. Ex-a5975
17. Us10301280, Compound P-2007
18. Us10301280, Compound P-2164
19. Hy-145557
20. Cs-0376032
21. 3,4-dimethyl-n-(2-phenyl-1h- Pyrrolo[2,3-b]pyridin-5-yl)-1h- Pyrazole-5-carboxamide
22. Wej
| Molecular Weight | 331.4 g/mol |
|---|---|
| Molecular Formula | C19H17N5O |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 331.14331018 g/mol |
| Monoisotopic Mass | 331.14331018 g/mol |
| Topological Polar Surface Area | 86.5 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Bezuclastinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bezuclastinib, including repackagers and relabelers. The FDA regulates Bezuclastinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bezuclastinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bezuclastinib supplier is an individual or a company that provides Bezuclastinib active pharmaceutical ingredient (API) or Bezuclastinib finished formulations upon request. The Bezuclastinib suppliers may include Bezuclastinib API manufacturers, exporters, distributors and traders.
Bezuclastinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bezuclastinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bezuclastinib GMP manufacturer or Bezuclastinib GMP API supplier for your needs.
A Bezuclastinib CoA (Certificate of Analysis) is a formal document that attests to Bezuclastinib's compliance with Bezuclastinib specifications and serves as a tool for batch-level quality control.
Bezuclastinib CoA mostly includes findings from lab analyses of a specific batch. For each Bezuclastinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bezuclastinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Bezuclastinib EP), Bezuclastinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bezuclastinib USP).
LOOKING FOR A SUPPLIER?
